Equity Profile

MRK

Merck & Co., Inc.

Health CarePharmaceuticals$298.3B

Apr30Thu

Post-Earnings Recap

ReportedQ1-2026Pre-Market6:30 AM EDT

Merck Beats on EPS, Stock Down 1.6%

Metric	Actual	Expected	Surprise
EPS	$-1.28	$-1.47	+15.46%
Revenue	N/A	$15.8B	N/A

management commentary, guidance changes, and full analysis available with Pro.

Merck Beats on EPS, Stock Down 1.6%

Key Numbers

Metric	Actual	Expected	Surprise
EPS	$-1.28	$-1.47	+15.46%
Revenue	N/A	$15.8B	N/A

Management Commentary

Tone: Unknown

No transcript is on record, and the analysis is based solely on numerical results.

What It Means

Merck's earnings report showed a better-than-expected EPS result, which was a positive surprise for investors. However, the stock still declined by 1.6% on the day, indicating that the market may have had concerns about other aspects of the company's performance or future outlook. The lack of revenue data and guidance may have contributed to the stock's negative reaction.

Company Snapshot

Merck & Co., Inc. is a major player in the pharmaceuticals sector, focusing on innovative medicines and vaccines....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of a company's profitability and is closely watched by investors.

-1.47

Revenue

Revenue figures provide insight into the company's sales performance and market demand for its products.

15.8B

Wall Street expectations, options signals, track record, and call prep available with Pro.

Original Pre-Earnings Preview

Context

Company Snapshot

Merck & Co., Inc. is a major player in the pharmaceuticals sector, focusing on innovative medicines and vaccines. With a market cap of $272 billion, the company is significant in the healthcare industry, particularly in areas like oncology and infectious diseases.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+5.60%

Avg Stock Reaction

-2.67%

Last Quarter Recap

In the last quarter, Merck reported an EPS of $2.04, slightly beating expectations. The stock reacted positively, gaining 2.18% the next day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Analysts are expecting a challenging quarter for Merck, with a consensus EPS of -1.47, indicating potential losses. Revenue expectations are set at $15.8 billion, reflecting cautious optimism.

Bull Case

If Merck can exceed EPS expectations and show strong revenue growth, it could signal robust demand for its products, leading to a positive stock reaction.

Bear Case

Conversely, if the company reports a larger loss than anticipated or revenue falls short, it could raise concerns about its market position and future growth.

Key Metrics to Watch

Earnings Per Share (EPS)

-1.47

EPS is a key indicator of a company's profitability and is closely watched by investors.

Revenue

15.8B

Revenue figures provide insight into the company's sales performance and market demand for its products.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will Merck's EPS come in better than the consensus estimate of -1.47?

This figure will be crucial in assessing the company's profitability and market confidence.

How does Merck's revenue of $15.8 billion compare to expectations?

Revenue performance will indicate demand for Merck's products and overall business health.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating Merck's ability to recover from recent challenges, particularly in oncology sales.

Supporting Evidence

Merck has consistently beaten EPS estimates in the past, suggesting potential for a surprise.

The options market is pricing a larger move than historical averages, indicating investor uncertainty.

Recent insider buying may suggest confidence in the company's recovery.

Key Risk

If Merck's oncology sales show unexpected strength, it could significantly alter the earnings outlook.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is debating whether Merck can maintain profitability amidst competitive pressures and market dynamics.

Bull Confirmed If

An EPS of -1.20 or better would confirm the bull case.

Bear Confirmed If

An EPS worse than -1.70 would confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±4.8%

Historical Avg

±3.6%

Pricing rich

The options market is pricing in a significant move, suggesting that investors expect volatility around the earnings announcement.

Options are pricing ±4.8% while MRK has averaged ±3.6% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.8%

30d HV

23.6%

Calls (878K)P/C Ratio: 0.74Puts (1.3M)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Merck beats EPS expectations, history suggests the stock could rise around 2.1% based on past performance.

In-Line / Cautious

If results are in line with expectations, the stock may see muted movement as investors await further guidance.

Miss

A miss could lead to a decline, with historical patterns indicating a potential drop around 2.1%.

Preparation

Congressional Activity

House & Senate STOCK Act disclosures over the trailing 6 months.

Trades

2 buys·1 sell

Members

House only

Est. Notional

$3,003.00–$45,000.00

disclosed dollar ranges

Most Active Members

D-NJJosh GottheimerRep.
1

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on the performance of Merck's oncology products.
2Management's commentary on market conditions and competitive pressures.
3Details on cost management strategies and their impact on profitability.
4Insights into future product pipeline developments and their expected contributions.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Apr27

DEAReported

Easterly Government Properties, Inc.

RecapView

Apr27

VZReported

Company Snapshot

Merck & Co., Inc. is a major player in the pharmaceuticals sector, focusing on innovative medicines and vaccines....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of a company's profitability and is closely watched by investors.

-1.47

Revenue

Revenue figures provide insight into the company's sales performance and market demand for its products.

15.8B

Wall Street expectations, options signals, track record, and call prep available with Pro.

Original Pre-Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+5.60%

Avg Stock Reaction

-2.67%

Last Quarter Recap

In the last quarter, Merck reported an EPS of $2.04, slightly beating expectations. The stock reacted positively, gaining 2.18% the next day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Analysts are expecting a challenging quarter for Merck, with a consensus EPS of -1.47, indicating potential losses. Revenue expectations are set at $15.8 billion, reflecting cautious optimism.

Bull Case

If Merck can exceed EPS expectations and show strong revenue growth, it could signal robust demand for its products, leading to a positive stock reaction.

Bear Case

Conversely, if the company reports a larger loss than anticipated or revenue falls short, it could raise concerns about its market position and future growth.

Key Metrics to Watch

Earnings Per Share (EPS)

-1.47

EPS is a key indicator of a company's profitability and is closely watched by investors.

Revenue

15.8B

Revenue figures provide insight into the company's sales performance and market demand for its products.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will Merck's EPS come in better than the consensus estimate of -1.47?

This figure will be crucial in assessing the company's profitability and market confidence.

How does Merck's revenue of $15.8 billion compare to expectations?

Revenue performance will indicate demand for Merck's products and overall business health.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating Merck's ability to recover from recent challenges, particularly in oncology sales.

Supporting Evidence

Merck has consistently beaten EPS estimates in the past, suggesting potential for a surprise.

The options market is pricing a larger move than historical averages, indicating investor uncertainty.

Recent insider buying may suggest confidence in the company's recovery.

Key Risk

If Merck's oncology sales show unexpected strength, it could significantly alter the earnings outlook.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is debating whether Merck can maintain profitability amidst competitive pressures and market dynamics.

Bull Confirmed If

An EPS of -1.20 or better would confirm the bull case.

Bear Confirmed If

An EPS worse than -1.70 would confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±4.8%

Historical Avg

±3.6%

Pricing rich

The options market is pricing in a significant move, suggesting that investors expect volatility around the earnings announcement.

Options are pricing ±4.8% while MRK has averaged ±3.6% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.8%

30d HV

23.6%

Calls (878K)P/C Ratio: 0.74Puts (1.3M)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Merck beats EPS expectations, history suggests the stock could rise around 2.1% based on past performance.

In-Line / Cautious

If results are in line with expectations, the stock may see muted movement as investors await further guidance.

Miss

A miss could lead to a decline, with historical patterns indicating a potential drop around 2.1%.

Preparation

Congressional Activity

House & Senate STOCK Act disclosures over the trailing 6 months.

Trades

2 buys·1 sell

Members

House only

Est. Notional

$3,003.00–$45,000.00

disclosed dollar ranges

Most Active Members

D-NJJosh GottheimerRep.
1

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on the performance of Merck's oncology products.
2Management's commentary on market conditions and competitive pressures.
3Details on cost management strategies and their impact on profitability.
4Insights into future product pipeline developments and their expected contributions.